Vaccines for HIV

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 8, 2000, Pages 1179-1188

  Dale, C J ^a   Kent, S J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adjuvant; Cellular immunity; HIV; Vaccine

Indexed keywords

ALPHA INTERFERON; DNA VACCINE; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; INACTIVATED VACCINE; INTERLEUKIN 11; INTERLEUKIN 12; LIVE VACCINE; NEF PROTEIN; PROTEIN SUBUNIT; RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ANTIGEN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MUCOSAL IMMUNITY; NONHUMAN; PATENT; PROTEIN TARGETING; REVIEW; VIRION; VIRUS INACTIVATION;

EID: 0033871719     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.8.1179     Document Type: Review

References (32)

1. The science of AIDS: A tale of two worlds
2. Control of sexually transmitted diseases for AIDS prevention in Uganda: A randomised community trial. Rakai Project Study Group
3. Anti-cell antibody in macaques
4. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy
5. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
6. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
7. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort
8. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
9. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
10. Direct gene transfer into mouse muscle in vivo
11. DNA vaccines for immunodeficiency viruses
12. Simian immunodeficiency virus DNA vaccine trial in macaques
13. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
14. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage
15. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus Type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
16. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
17. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant poxvirus booster immunizations
18. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection
19. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
20. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
21. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine
22. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection
23. The antigenic structure of the HIV gp120 envelope glycoprotein
24. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
25. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
26. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
27. Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowlpox viruses
28. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection
29. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
30. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers
31. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
32. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: Potential mechanism of vaccine failure